Home
Scholarly Works
Benralizumab Significantly Reduced Oral...
Conference

Benralizumab Significantly Reduced Oral Corticosteroid Dosages And Asthma Exacerbation Rates For Patients With Severe, Uncontrolled Asthma: Results Of The Zonda Phase Iii Trial

Authors

Nair P; Wenzel SE; Rabe K-F; Bourdm A; Lugogo N; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M

Volume

195

Publisher

AMER THORACIC SOC

Publication Date

January 1, 2017

Name of conference

International Conference of the American-Thoracic-Society (ATS)

Conference place

Washington, DC

Conference start date

May 19, 2017

Conference end date

May 24, 2017

Conference proceedings

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ISSN

1073-449X

Contact the Experts team